Thrombotic Thrombocytopenic Purpura in the Setting of Cirrhosis and Baseline Thrombocytopenia

TL;DR

This paper discusses the challenges of treating immune thrombotic thrombocytopenic purpura in a patient with cirrhosis and pre-existing low platelet count.

Contribution

The paper presents a case and perspective on managing iTTP in patients with severe baseline thrombocytopenia and high bleeding risk.

Findings

Managing iTTP in patients with cirrhosis and low platelet count is complicated by treatment limitations and bleeding risks.

Current guidelines lack clarity for treating iTTP in patients with significant comorbidities.

The case highlights the need for individualized treatment strategies in high-risk patients.

Abstract

The management of immune thrombotic thrombocytopenic purpura (iTTP) has evolved significantly over the past several years. However, despite recent advances, there are limited tools available for patients with comorbidities that preclude either the utilization of available treatment modalities or evidence-based laboratory target levels. Literature to guide the management of such patients is sparse at best, and many complications associated with pre-existing comorbidities in the context of iTTP have not been reported. Here we describe the case of a patient with severe thrombocytopenia at baseline due to liver cirrhosis who developed iTTP. The challenges of the case in terms of pursuing disease-directed treatment, defining laboratory parameters to guide treatment, and mitigating the risks of bleeding and disease exacerbation are discussed. We offer our perspective in treating iTTP in the setting of severe baseline thrombocytopenia and high bleeding risk.

Figures